Mitochondrial disorders are one of the most challenging collections of human diseases impacting nearly 1:4000 live births (Vafai and Mootha 2013; Stewart and Chinnery 2015) and often affect the nervous system. Most of these disorders are due to biochemical lesions in the oxidative phosphorylation (OXPHOS) system, the organelle's core pathway responsible for making adenosine triphosphate (ATP) by consuming the oxygen we breathe. The OXPHOS system is encoded both by the nuclear and mitochondrial (mtDNA) genomes. To date, nearly 250 different monogenic forms of mitochondrial disease, involving both genomes, have been described. Each one impacts a different subset of organ systems. The genetic, biochemical, and clinical heterogeneity has made the diagnosis and management of these disorders incredibly difficult, since no two cases present identically.
At present, we have no proven therapies for mitochondrial disease (Pfeffer et al. 2013 ), but one of the mainstays of clinical management is to avoid toxic exposures. Our mitochondria have a mosaic evolutionary history (Vafai and Mootha 2012) : their DNA replication machinery resembles that of viruses, while their translation machinery resembles that of bacteria. Indeed, antiviral drugs and certain antibiotics can cross-react with our mitochondria and cause toxicity. For example, the first-generation nucleoside reverse transcriptase inhibitors used to treat HIV infection can cause reversible mtDNA depletion myopathy (Arnaudo et al. 1991; Payne et al. 2011) ; and the treatment of hepatitis B with fialuridine can cause fatal lactic acidosis and liver-failure (McKenzie et al. 1995; Young 2017) . In addition, carriers of the m.1555A > G mtDNA variant are at risk of deafness when exposed to aminoglycosides (Prezant et al. 1993) . These drugs are best avoided in patients with specific forms of mitochondrial disease, unless strongly indicated clinically.
Patients with mitochondrial disorders often present with a clinical deterioration associated with infection, typically involving the respiratory tract. Confusion, depressed consciousness, and seizures are often accompanied by tachypnea either due to a respiratory tract infection or in response to lactic acidosis (Kussmaul dyspnoea). Not surprisingly, in the hyper acute setting, this prompts the use of immediate high-flow oxygen in the Emergency Room or Intensive Care Unit. However, mounting evidence suggests that too much oxygen might do more harm than good in some circumstances.
Anecdotally, some mitochondrial patients receiving supplemental oxygen via hyperbaric oxygen therapy (HBOT) suffer adverse effects within 24 h of exposure. This prompted a statement from the United Mitochondrial Disease Foundation back in 2010, which highlighted the lack of evidence supporting a role for HBOT as a treatment mitochondrial disease, and emphasized the potential toxic effects (http://www.umdf.org/wp-content/uploads/2017/11/HBOT. pdf). Until recently, there has been a lack of evidence in the published literature to support these claims, but new preclinical data has brought concerns sharply back into focus, casting light on the potential underlying mechanisms.
One of our labs recently performed a CRISPR screen to identify genetic modifiers of mitochondrial dysfunction (Jain et al. 2016 ). The genetic screen spotlighted the oxygen sensing pathway-an evolutionarily conserved physiological program designed to allow organisms to cope with fluctuations in environmental oxygen. This prompted us to investigate the effects of environmental oxygen on a genetic mouse model of Leigh syndrome, a classical form of mitochondrial neurodegeneration (Jain et al. 2016) . At 21%, the oxygen tension at Communicated by: Shamima Rahman sea level, the mouse model undergoes a stereotyped disease trajectory mimicking the human disorder, with progressive weight loss, hypothermia, and death from subacute neurodegeneration with a median survival of 55 days. Remarkably, when housed in 11% oxygen, the mice regained their body weight and temperature and enjoy a fivefold extension in life span with dramatically improved neurological recovery. However, strikingly, at 55% inspired oxygen, in order to generate hyperoxia (a level not uncommon in the ICU or the operating room), the Leigh syndrome mice died within days-an effect not seen in wild-type (normal) mice.
How can we explain these striking observations of oxygen toxicity in a mouse model of mitochondrial disease? We still do not have a full mechanistic understanding, but we offer our current hypothesis. Mitochondria are major consumers of oxygen, and in the setting of mitochondrial dysfunction, there may be high unused oxygen. In fact, it is known that oxygen is poorly consumed in patients with mitochondrial disease, leading to venous hyperoxia and impaired peripheral oxygen extraction during exercise (Taivassalo et al. 2002) . We speculate that the unused oxygen may have two potentially detrimental effects. First, high oxygen levels may actually suppress glycolysis via allosteric and transcriptional mechanisms. Our body's biochemical programs are designed to shift the reliance towards glycolysis (which does not require oxygen) when oxygen levels are low. This allows modern humans to adapt to low oxygen levels found at high altitude, and also may reflect ancient prehistory, when the global atmospheric oxygen was much lower. While ordinarily an adaptive mechanism to create energy efficiently based on sensing O 2 availability, in the setting of mitochondrial dysfunction, the higher unused oxygen may limit the activation of glycolysis at the very time they require it. Second, high unused oxygen is likely to be directly toxic by leading to the formation of reactive oxygen species and directly inactivating enzyme systems, such as aconitase, that are oxygen-labile (Morton et al. 1998 ) (Campian et al. 2004) . Crucially, supplemental oxygen in the face of mitochondrial dysfunction could exacerbate problems via both mechanisms. Although the precise mechanisms still remain to be elucidated, it is notable that studies in other model genetic systems, such as Drosophila have also suggested supplemental oxygen can be toxic to mitochondrial mutants (Walker et al. 2006) .
Oxygen toxicity has been recognized for some time in adults after cardiac arrest (Kilgannon et al. 2011) , following acute brain injury (Vilalta et al. 2011) or stroke (Rincon et al. 2014) . It is also intriguing that in the ICU, conservative (target O2 sat of 95-97%) versus conventional (target O2 sat of 98-100%) oxygen therapy results in superior outcomes (Girardis et al. 2016 ). The traditional view was that oxygen delivery is inadequate for an increased tissue oxygen consumption in sepsis, driving strategies to increase tissue oxygenation. However, there is increasing awareness that this approach might actually do harm, as sepsis physiology is often characterized by an inability to utilize oxygen, resulting in a mismatch between oxygen delivery and consumption. The concept that excess supplemental oxygen can be toxic more generally is supported by a recent meta-analysis of 25 randomized trials, including 16,037 patients with sepsis, critical illness, stroke, trauma, myocardial infarction, cardiac arrest, or who had emergency surgery; where liberal oxygen therapy increased mortality without improving patient-related outcomes (Chu et al. 2018) . This meta-analysis concluded that in acutely ill adults, an oxygen saturation above 94-96% may become unfavorable. There is emerging evidence supporting the role of mitochondrial dysfunction in these different common disorders, providing a plausible mechanistic link between clinical observations in the critical care unit and the preclinical studies in animal models with genetically defined defects of the mitochondrial respiratory chain. A more refined understanding of the balance between oxygen needs and delivery may therefore have broad relevance for medicine. However, preclinical mouse findings highlight an urgent need to determine how to best use oxygen in patients with rare mitochondrial diseases to prevent doing harm.
At present, we do not know whether high supplemental oxygen may be toxic in human patients with genetic mitochondrial disease. Mitochondrial disorders are notoriously heterogeneous at the genetic, biochemical, and clinical level, and each genetically defined mitochondrial disorder is ultrarare-so there is no reason to assume that all will behave the same in response to high oxygen exposure. To advance understanding, centers across the world must therefore work together. In the short term, we should determine whether high-dose oxygen is harmful in patients with mitochondrial disease. All available retrospective data should be collated, and moving forward, data on oxygen use should be systematically collected in a standardized format. Other than mortality, or length-of-stay in the intensive care unit during or after high oxygen delivery, it will be difficult to objectively define adverse outcomes, given the heterogeneity of these disorders. The data collection itself will also present logistical challenges, including local review board approvals for single patients, and the need to comply with national data security requirements. Despite our best efforts, the results of this work may be inconclusive because of the clinical heterogeneity and difficulties in retrospectively estimating tissue oxygenation. However, we believe it is important to collect this information to lay an evidence base for a future, controlled prospective study. Following the retrospective data collection, we advocate a randomized trial comparing traditional (liberal) oxygen therapy with conservative oxygen therapy, and only enrolling patients with no clinically demonstrable tissue hypoxia (which is a challenge in itself). A challenge lies in identifying quantitative biomarkers (Steele et al. 2017 ) that could help determine whether oxygen is helpful or toxic in a longitudinal cross-over study design. However, working closely with international patient groups will help determine whether the proposed study design presents an acceptable balance of the risks and benefits. Engaging patients from the outset will undoubtedly help boost recruitment, which is critical for any rare disease study.
Clearly, we must continue to use oxygen if there is evidence of tissue hypoxia. From our perspective, oxygen should be used judiciously in patients with mitochondrial diseases, with careful monitoring of clinical outcomes, such as consciousness, cognition, and seizure activity. If there is an obvious deterioration during oxygen therapy, it would seem wise to carefully control the oxygen delivery and closely monitor oxygenation until we have a more robust evidence base to guide clinical practice. 
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